Naslov
Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
(Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review)

Autori
Gamulin, Marija ; Nham, Eric ; Rkman, Deni ; Antunac Golubić, Zrna ; Likić, Robert

Izvornik
Croatian medical journal (0353-9504) 61 (2020), 4; 326-332

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
renal cell cancer ; nivolumab
(rnal cell cancer ; nivolumab)

Sažetak
Aim To assess diseases outcomes and tolerability of reallife second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. Methods This retrospective chart review involved prospectively monitored patients (named patient program) treated with second-line nivolumab for mRCC at the University Hospital Centre Zagreb from February 2016 to March 2018. Results The study enrolled 30 patients, 5 of whom (16.7%) had a complete response. The mean±standard deviation therapeutic response time to nivolumab treatment was 14.07±8.92 months, with a minimum treatment duration of 2 months and a maximum of 24 months. The median duration of therapy was 17 months (mean: 15.8 months ; range: 3-24 months), and 50% (n=15/30) of patients remained alive at the end of follow up. The most common adverse events associated with nivolumab were fatigue (26.67% ; n=8/30), anemia (10.0% ; n=3/30), adrenal insufficiency (6.67% ; n=2/30: G1=1, G2=1), grade 2 pneumonitis (6.67% ; n=2/30), grade 2 neuropathy (6.67% ; n=2/30), rash (6.67% ; n=2/30: G1=1, G2=1), and hepatitis (3.33% ; n=1/30). Conclusion The present study indicates acceptable patient responses and tolerability of nivolumab in mRCC.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA